GSP Crop Science Q3 and 9M FY26: B2C-Led Growth, Higher EBITDA, and a Bigger Patented Products Push

GSP Crop Science Limited shared its investor presentation and concall commentary for the quarter and nine months ended December 31, 2025. The company operates across insecticides, herbicides, fungicides, and plant growth regulators, selling through domestic B2B, domestic B2C, and exports.

For 9M FY26, consolidated revenue rose 14% to INR 11,146 million from INR 9,794 million in 9M FY25. Consolidated EBITDA increased 32% to INR 1,538 million, with margin expanding to 13.80% from 11.92%. Consolidated PAT grew 26% to INR 751 million, with margin improving to 6.74% from 6.09%.

The quarter, however, was weaker. Q3 FY26 consolidated PAT was a loss of INR 60 million (vs loss of INR 62 million in Q3 FY25). The company did not provide a full segment table in the documents, but the presentation attributed the nine-month growth primarily to the domestic B2C segment.

What drove the nine-month growth

The investor presentation linked 9M FY26 revenue growth mainly to an increase in business under domestic B2C. It cited new product sales of INR 366 million and highlighted higher sales in specific brands including PCT-410 (up INR 80 million), Torch (up INR 107 million), Aurthor (up INR 90 million), and Runout (up INR 47 million).

On the concall, management explained the company’s go-to-market structure as three verticals: domestic B2B, domestic B2C, and exports. The CFO stated the revenue split is approximately 40% domestic B2B, 40% domestic B2C, and 20% exports, with exports spanning 37 countries.

The call also provided a product-level anecdote on PCT-410. Management described it as a seed treatment product and said it scaled to around INR 50 crores to INR 70 crores of business for the brand within two to three years. This disclosure helped connect the B2C growth narrative to a concrete product outcome, although it did not reconcile to the INR 80 million increase noted in the presentation.

Patents, R&D, and why management thinks margins can hold up

The strategic thread running through both the presentation and the concall is differentiation through in-house R&D and patented combinations. The investor presentation stated the company has 102 granted patents and 108 patent applications under process. It also highlighted its regulatory base: 219 formulation registrations and 63 technical registrations in India (with additional export registrations mentioned separately).

On the concall, management said it has commercialized 12 patented products so far, and it launched one product during FY26. They described their approach as launching off-patent technical molecules and then creating novel combination products designed to solve multiple farmer problems with a single solution. Management stated that patented products contributed around 20% of revenues and that they deliver a premium versus generics, quantified as roughly 20% to 25% higher at the gross margin level.

The nine-month EBITDA expansion was positioned as a function of higher B2C volumes and a richer product mix. This aligns with the company’s stated goal to raise patented products contribution over time. Management went further and stated that over the next three years, it broadly expects 40% to 50% of revenue could come from such products. This statement was presented as an expectation rather than a formal guidance framework.

Operations, capacities, and near-term risk management

GSP Crop Science operates five manufacturing facilities in India, including technical plants, formulation plants, and an intermediates facility. The presentation disclosed installed capacities by site and category. The concall added utilization commentary: formulation capacity utilization is typically 30% to 40% due to seasonal demand patterns, while technical plants run at 70% to 75% utilization, with peak potential around 90%.

When asked about scale, management said that with the current revenue mix (stated as roughly 75% formulations and 25% technicals), peak utilization could support revenue of about INR 1,900 crores to INR 2,000 crores. Management also noted debottlenecking potential within the same facilities and emphasized that newer chemistries are low-volume, high-value products.

The concall also addressed the impact of the Middle East conflict through crude prices, raw material inflation, and logistics. Management stated it has increased prices by about 10% to 15% from April 1 to pass on higher costs. It also noted that B2B pricing tends to be more elastic, while in B2C there can be a lag in passing on costs due to channel inventory and competition. The company said it typically maintains around 45 days inventory for imported raw materials. It flagged that if logistics disruption continues for another month or so, supply could be impacted, but said it is currently covered.

On sourcing, management said intermediates for manufacturing technicals are mostly imported from China. It also described backward integration efforts via intermediates manufacturing to reduce China dependency. The presentation lists an intermediates facility at Saykha with installed capacity of 5,400 MT.

Finally, on weather risk, management responded to a question on El Nino by saying it does not expect a major challenge because it is strong in paddy, where irrigation support is relatively better.

Takeaways

Across the nine months ended December 31, 2025, GSP Crop Science delivered consolidated revenue growth of 14% and EBITDA growth of 32%, with improved margins. The company’s narrative is anchored in its patented combinations and in-house R&D, with management stating patented products contribute around 20% of revenue today and could rise materially over the next three years.

At the same time, the documents show clear execution realities. Q3 results were loss-making at the PAT level, formulation utilization remains structurally low due to seasonality, and sourcing remains China-linked for key intermediates. The near-term test will be how smoothly cost inflation and logistics delays are managed during the upcoming season, and how quickly the newer patented products scale without heavy pricing or channel friction.